End-organ damage in hypertensive transgenic ren-2 rats: Influence of early and late endothelin receptor blockade

Physiological Research

Volumn 58, Issue SUPPL.2, 2009, Pages 69-78

  Vernerova Z ^a,b   Kujal, P ^a,b   Kramer, H J ^c   Backer A ^c   Cervenka L ^a,b,d   Vaneckova I ^a,d  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d Center for Cardiovascular Research   (Czech Republic)

Author keywords

Endothelin receptors; Hypertension; Morphology; Podocytes; Ren 2 rats

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATRASENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; PYRROLIDINE DERIVATIVE; REN2 PROTEIN, MOUSE; RENIN; SULFONAMIDE;

ANIMAL; BLOOD PRESSURE; DISEASE COURSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; GENETICS; HETEROZYGOTE; HOMOZYGOTE; HYPERTENSION; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PODOCYTE; RAT; REVIEW; SALT INTAKE; TIME; TRANSGENIC RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIN-1; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HETEROZYGOTE; HOMOZYGOTE; HYPERTENSION; MALE; PODOCYTES; PYRROLIDINES; RATS; RATS, TRANSGENIC; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RENIN; SODIUM CHLORIDE, DIETARY; SULFONAMIDES; TIME FACTORS;

EID: 77949529514     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (35)

1. CALLAHAN MF, LI P, FERRARIO CM, GANTEN D, MORRIS M: Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 27: 573-577, 1996.
2. CHUNG O, SCHIPS T, ROHMEISS P, GRETZ N, STRAUCH M, UNGER T: Protein excretion and renal adaptation of transgenic mRen2 rats to changing oral sodium loads. J Hypertens 11 (Suppl 5): S188-S189, 1993.
3. DAHL LK, KNUDSEN KD, HEINE MA, LEITL GJ: Effects of chronic excess salt ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ Res 22: 11-18, 1968.
4. DURVASULA RV, SHANKLAND SJ: Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am J Physiol 289: F577-F584, 2005.
5. DVOŘÁK P, KRAMER HJ, BÄCKER A, MALÝ J, KOPKAN L, VANĚČKOVÁ I, VERNEROVÁ Z, OPOČENSKÝ M, TESAŘ V, BADER M, GANTEN D, JANDA J, ČERVENKA L: Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats. Kidney Blood Press Res 27: 248-258, 2004.
6. FERRARI P, BARBER BR, TORIELLI L, FERRANDI M, SALARDI S, BIANCHI G: The Milan hypertensive rat as a model for studying cation transport abnormality in genetic hypertension. Hypertension 10: 132-136, 1987.
7. FLOEGE J, ALPERS CE, BURNS MW, PRITZL P, GORDON K, COUSER WG, JOHNSON RJ: Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 66: 485-497, 1992.
8. GOMEZ-SANCHEZ EP, ZHOU M, GOMEZ-SANCHEZ CE: Mineralocorticoids, salt and high blood pressure. Steroids 61: 184-188, 1996.
9. INA K, KITAMURA H, TATSUKAWA S, TAKAYAMA T, FUJIKURA Y: Glomerular podocyte endocytosis of the diabetic rat. J Electron Microsc (Tokyo) 51: 275-279, 2002.
10. JACINTO SM, MULLINS JJ, MITCHEL KD: Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol 276: F315-F322, 1999.
11. KASHGARIAN M, STERZEL RB: The pathobiology of the mesangium. Kidney Int 41: 524-529, 1992.
12. KOLETSKY S, PAVLICKO KM, RIVERA VELEZ JM: Renin angiotensin activity in hypertensive rats with a single ischemic kidney. Lab Invest 24: 41-44, 1971.
13. LANGHEINRICH M, LEE MA, BÖHM M, PINTO YM, GANTEN D, PAUL M: The hypertensive Ren-2 transgenic rat TGR (mRen 2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 9: 506-512, 1996.
14. LANTELME P, MING LO, LUTTENAUER L, SASSARD J: Pivotal role of the renin-angiotensin system in Lyon hypertensive rats. Am J Physiol 273: R1793-R1799, 1997.
15. MENEELY GR, BALL COT: Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride. Am J Med 25: 713, 1958.
16. MULLINS JJ, PETERS J, GANTEN D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature (Lond) 344: 541-544, 1990.
17. NAGASE M, SHIBATA S, YOSHIDA S, NAGASE T, GOTODA T, FUJITA T: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093, 2006.
18. OKAMOTO AK: Development of a strain of spontaneously hypertensive rat. Jpn Circ J 27: 282-293, 1963.
19. OPOČENSKÝ M, DVOŘÁK P, MALÝ J, KRAMER HJ, BÄCKER A, KOPKAN L, VERNEROVÁ Z, TESAŘ V, ZIMA T, BADER M, GANTEN D, JANDA J, VANĚČKOVÁ I: Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats. Physiol Res 53: 581-593, 2004.
20. OPOČENSKÝ M, KRAMER HJ, BÄCKER A, VERNEROVÁ Z, EIS V, ČERVENKA L, ČERTÍKOVÁ-CHÁBOVÁ V, TESAŘ V, VANĚČKOVÁ I: Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48: 965-971, 2006.
21. PAVENSTÄDT H, KRIZ W, KRETZLER M: Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2002.
22. PINTO YM, PAUL M, GANTEN D: Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 39: 77-88, 1998.
23. PUGLIESE G, RICCI C, IACOBINI C, MENINI S, FIORETTO P, FERRANDI M, GIARDINO LA, ARMELLONI S, MATTINZOLI D, RASTALDI MP, PUGLIESE F: Glomerular barrier dysfunction in glomerulosclerosisresistant Milan rats with experimental diabetes: the role of renal haemodynamics. J Pathol 213: 210-218, 2007.
24. ROUX S, BREU V, ERTEL SI, CLOZEL M: Endotelin antagonism with bosentan: a review of potential applications. J Mol Med 77: 364-376, 1999.
25. ST JOHN PL, ABRAHAMSON DR: Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. Kidney Int 60: 1037-1046, 2001.
26. STRUTZ F, CARON P, TOMASZEWSKI I, FUMO P, ZIYADEH F, NEILSON EG: Transdifferentiation: a new concept in renal fibrogenesis. J Am Soc Nephrol 5: 819, 1994.
27. TRYGGVASON K, WARTIOWAARA J: Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10: 543-549, 2001.
28. VANĚČKOVÁ I, KRAMER H, BÄCKER A, VERNEROVÁ Z, OPOČENSKÝ M, ČERVENKA L: Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46: 969-974, 2005.
29. VANĚČKOVÁ I, KRAMER HJ, BÄCKER A, SCHEJBALOVÁ S, VERNEROVÁ Z, EIS V, OPOČENSKÝ M, DVOŘÁK P, ČERVENKA L: Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vascul Pharmacol 45: 163-170, 2006.
30. VERNEROVÁ Z, KRAMER HJ, BÄCKER A, ČERVENKA L, OPOČENSKÝ M, HUSKOVÁ Z, VANOURKOVÁ Z, EIS V, ČERTÍKOVÁ-CHÁBOVÁ V, TESAŘ V, MALÝ J, VANĚČKOVÁ I: Endothelin receptor blockade in hypertensive heterozygous Ren-2 transgenic rats. Vascul Pharmacol48: 165-73, 2008.
31. VONGWIWATANA A, TASANARONG A, RAYNER DC, MELK A, HALLORAN PF: Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5: 1367-1374, 2005.
32. WEINBERGER MH: Salt sensitivity: does it play an important role in the pathogenesis and treatment of hypertension? Curr Opin Nephrol Hypertens 5: 205-208, 1996
33. WHITWORTH CE, VENIANT MM, FIRTH JD, CUMMING AD, MULLINS JJ: Endothelin in the kidney in malignant phase hypertension. Hypertension 26: 925-931, 1995.
34. YANAGISAWA M, KURIHARA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K, MASAKI T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
35. ZICHA J, KUNEŠ J: Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 79: 1227-1282, 1999.